DelveInsight’s ’Epstein–Barr virus (EBV) – Market Insights, Epidemiology, and Market Forecast?2030’ report deliver an in-depth understanding of the Epstein–Barr virus (EBV), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Epstein–Barr virus (EBV) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted EBV symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Epstein–Barr virus (EBV) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan



Study Period: 2017–2030
Epstein–Barr virus (EBV) Disease Understanding and Treatment Algorithm
Epstein–Barr virus (EBV) Overview
Epstein–Barr virus (EBV) is a member of the Herpesviridae family and is a ubiquitous pathogen that is persistently harbored by people throughout the world. EBV is the major cause of infectious mononucleosis and is associated with several malignancies. EBV is an oncogenic virus and continued to attract considerable attention worldwide, primarily due to its oncogenic properties and its association with several human malignancies, including Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC), post-transplant lymphoproliferative disease (PTLD) after organ or stem cell transplant, Hodgkin’s lymphoma (HL) and gastric carcinoma (GC). A detailed understanding of the risk factors or causes of cancer is of paramount importance for any future prevention strategies.
The sign and symptoms of IM comprise fatigue, fever, nausea, sore throat, cough, body aches, rash, photophobia, swollen lymph nodes in the neck and armpits, and rarely, splenomegaly (enlarged spleen) and hepatomegaly (enlarged liver). Primary EBV infection or reactivation in the immunocompromised host (particularly those post-hematopoietic stem cell transfer or solid organ transfer) may present as a life-threatening disease characterized by fever, lymphadenopathy, mononucleosis-like syndrome, central nervous system (CNS) disease/myelitis, pneumonia, sepsis-like syndrome, and PTLD. EBV can infect a wide range of cells and tissues including T and B lymphocytes, nasopharynx and oropharynx squamous epithelial cells, salivary and stomach glands, thyroid glandular epithelial cells, smooth muscle, and follicular dendritic cells. However, EBV primarily infects and replicates in the stratified squamous epithelium of the oropharynx, followed by a latent infection of B lymphocytes.
In the context of treatment, at present, there is no specific treatment for IM. Management focuses on symptomatic relief, and patients are therefore treated with simple anti-viral drugs, analgesics, antipyretics, hydration, and rest. Additionally, for the treatment of EBV-associated diseases investigational therapies and the treatment of PTLD, particularly in the setting of allogeneic hematopoietic stem cell transplant (HSCT) where adoptive immunotherapy (either donor lymphocyte infusion or infusion of EBV-specific lymphocytes) has demonstrated to be effective.
Epstein–Barr virus (EBV) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Epstein–Barr virus (EBV) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Epstein–Barr virus (EBV) market report gives a thorough understanding of EBV symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides EBV symptoms of treatment algorithms and treatment guidelines for EBV symptoms in the US, Europe, and Japan.
Epstein–Barr virus (EBV) Epidemiology
Epstein–Barr virus symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Epstein–Barr virus (EBV) epidemiology segmented as the Total Diagnosed cases of EBV Infectious Mononucleosis, Total Incident cases of EBV+ Cancers, Total Incident cases of EBV+ PTLD. The report includes the scenario of EBV symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Epstein–Barr virus (EBV) Epidemiology
The epidemiology segment also provides the Epstein–Barr virus (EBV) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
In 2020, the total diagnosed cases of EBV Infectious Mononucleosis in the US were found to be 162,800; whereas the EBV Lymphoma such as the Burkitt lymphoma (BL), Hodgkin lymphoma (HL) is in 1,555; 9,548 respectively. The EBV-cancer such as Gastric carcinoma (GC) cases were 27,619, and nasopharyngeal carcinoma (NPC) cases were 2,197 for the year 2020.
Epstein–Barr virus (EBV) Drug Chapters
The drug chapter segment of the Epstein–Barr virus (EBV) report encloses the detailed analysis of EBV marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Epstein–Barr virus (EBV) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Treatment is generally supportive of mononucleosis. Antipyretics and anti-inflammatory medications help treat fever, sore throat, and the general fatigue seen in this illness. Hydration, rest, and good nutritional intake should also be encouraged. Corticosteroids are not generally recommended in the routine treatment of mononucleosis because of concerns with immunosuppression; however, in cases of airway obstruction, corticosteroids are indicated along with appropriate airway management.
Products detail in the report?
Epstein–Barr virus (EBV) Emerging Drugs
Viralym-M (AlloVir) is a multi-virus specific T cell therapy (VST) targeting five devastating viral pathogens: BK virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein–Barr Virus (EBV), and Human Herpesvirus 6 (HHV-6), that has the potential to transform care for transplant recipients as well as individuals who are at high risk for opportunistic viral infections by reducing or preventing disease morbidity and dramatically improving patient outcomes. The drug has received Orphan Drug Designation, Priority Medicines (PRIME) designation in EU and Regenerative Medicine Advanced Therapy (RMAT) designation from the US for the treatment of serious infections with BK virus, cytomegalovirus, human herpes virus-6, Epstein–Barr virus, and/or adenovirus in allogeneic hematopoietic stem cell transplantation (HSCT) recipients.
Products detail in the report?
Epstein–Barr virus (EBV) Market Outlook
The Epstein–Barr virus (EBV) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Epstein–Barr virus (EBV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Epstein–Barr virus (EBV) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Epstein–Barr virus (EBV) market in 7MM is expected to change in the study period 2017–2030.

Key Findings
This section includes a glimpse of the Epstein–Barr virus (EBV) market in 7MM. The market size of EBV in the seven major markets was found to be USD 1,673.44 million in 2020.
The United States Market Outlook
This section provides a total of Epstein–Barr virus (EBV) market size and market size by therapies in the United States.
The United States accounts for the highest market size of EBV in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Treatment options for EBV-PTLD include manipulating the balance between outgrowing EBV-infected B cells and the EBV CTL response and targeting the B cells with monoclonal antibodies or chemotherapy. In EBV-PTLD, select cases may benefit from the reduction of immunosuppression as the sole intervention or as part of the treatment plan. The current treatment market majorly includes the CD-20 Targeted Rituximab as monotherapy or Rituximab in combination with CHOP to control the cell proliferation in tumors and PTLD.
EU-5 Countries: Market Outlook
EBV-specific cytotoxic T-cell infusions have proven effective in EBV-PTLD and expanding such adoptive immunotherapies to other EBV-related malignancies is an area of active research. However, other EBV-related lymphomas typically have more restricted, less immunogenic arrays of viral antigens to target with adoptive immunotherapy compared to EBV-PTLD therapeutically. Furthermore, the malignant EBV-positive tumor cells of Hodgkin lymphoma are scattered amid a dense infiltrate of regulatory T-cells, macrophages, and other cells that may dampen the anti-tumor efficacy of adoptive immunotherapy. Strategies to overcome these obstacles are areas of ongoing pre-clinical and clinical investigations.
Although a wide number of studies are related to EBV detection, studies investigating the EBV viremia and genetic variability in healthy individuals are still limited, although this virus is transfusion transmissible and linked to PTLDs and a wide range of other malignancies. Estimates of EBV infection are important to give researchers and clinicians accurate data concerning the prevalence of the virus, and consequently, improving the safety of health practices to eliminate the EBV spread, especially in blood banks, and organ transplantation centers where EBV constitutes a life-threatening risk to recipients.
Japan Market Outlook
The total Epstein–Barr virus (EBV) market size and market size by therapies in Japan are also mentioned.
Epstein–Barr virus (EBV) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers the Epstein–Barr virus (EBV) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Epstein–Barr virus (EBV) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses the Epstein–Barr virus (EBV) key players involved in developing targeted therapeutics.
Major players include Brentuximab Vedotin (Seagen) is evaluated as the first line of therapy, whereas Tabelecleucel (Atara Biotherapeutics), Viralym-M (AlloVir), TT10 (Tessa Therapeutics), VRx-3996 + Valganciclovir (Viracta Therapeutics), FLX475 (RAPT Therapeutics)
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Epstein–Barr virus (EBV) emerging therapies.
Reimbursement Scenario in Epstein–Barr virus (EBV)
The cost-effectiveness model adapted from the Institute of Medicine (IOM) study of priorities for vaccine development proposed that the EBV vaccine was feasible and that licensure could occur within the time frame of its charge but was not imminent. The model estimated that it would take 15 years until licensure and that USD 390 million needed to be invested. Furthermore, it was estimated that this would be a relatively low-cost vaccine, costing USD 50 per dose. Vaccine administration would cost an additional USD 10. The committee accepted default assumptions for the vaccine that it would require a series of three doses and that effectiveness would be 75%.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Epstein–Barr virus (EBV) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or the Epstein–Barr virus (EBV) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Epstein–Barr virus (EBV) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report

  • The report covers the descriptive overview of Epstein–Barr virus (EBV), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Epstein–Barr virus (EBV) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Epstein–Barr virus (EBV) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Epstein–Barr virus (EBV) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epstein–Barr virus (EBV) market



Report Highlights

  • In the coming years, Epstein–Barr virus (EBV) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epstein–Barr virus (EBV) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for EBV. The launch of emerging therapies will significantly impact the Epstein–Barr virus (EBV) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for EBV.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Epstein–Barr virus (EBV) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Epstein–Barr virus (EBV) Pipeline Analysis
  • Epstein–Barr virus (EBV) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies



Epstein–Barr virus (EBV) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Epstein–Barr virus (EBV) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake


Epstein–Barr virus (EBV) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions
Market Insights:

  • What were the Epstein–Barr virus (EBV) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Epstein–Barr virus (EBV) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Epstein–Barr virus (EBV) market Size during the forecast period (2017–2030)?
  • At what CAGR, the Epstein–Barr virus (EBV) market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Epstein–Barr virus (EBV) market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Epstein–Barr virus (EBV) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Epstein–Barr virus (EBV)?
  • What is the historical Epstein–Barr virus (EBV) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Epstein–Barr virus (EBV) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Epstein–Barr virus (EBV)?
  • Out of all 7MM countries, which country would have the highest population of Epstein–Barr virus (EBV) during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Epstein–Barr virus (EBV)?
  • What are the current treatment guidelines for the treatment of Epstein–Barr virus (EBV) in the USA, Europe, and Japan?
  • What are the Epstein–Barr virus (EBV) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Epstein–Barr virus (EBV)?
  • How many therapies are developed by each company for the treatment of Epstein–Barr virus (EBV)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Epstein–Barr virus (EBV)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Epstein–Barr virus (EBV) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Epstein–Barr virus (EBV) and their status?
  • What are the key designations that have been granted for the emerging therapies for Epstein–Barr virus (EBV)?
  • What are the global historical and forecasted market of Epstein–Barr virus (EBV)?



Reasons To Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Epstein–Barr virus (EBV) market
  • To understand the future market competition in the Epstein–Barr virus (EBV) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Epstein–Barr virus (EBV) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Epstein–Barr virus (EBV) market
  • To understand the future market competition in the Epstein–Barr virus (EBV) market